AI, Biotech, And Federal Investment A Generational Opportunity For NC's Research Universities

By Penny Gordon-Larsen, Ph.D.

AI is beginning to reshape drug discovery, but technical progress alone will not determine its impact. Success depends on the quality of training data, the expertise of the people developing and validating AI systems, and the ability to translate promising research into viable therapies. At the same time, a constrained biotech funding environment and growing pharmaceutical interest in later-stage assets are raising expectations for translational readiness. These pressures create a widening gap between scientific opportunity and investment priorities. Closing it will require capable leadership, exceptional talent, and sustained collaboration among researchers, private industry, investors, and the federal government.

Explore the systemic constraints influencing AI-enabled drug discovery and the partnerships needed to move innovation forward.